HK Stock Market Move | SINOMAB BIO-B(03681) rose more than 18%. The company withdrew the application for the marketing of rituximab for the treatment of RA. The drug has the potential to treat SLE.

SINOMAB BIO-B (03681) rose by more than 18%, reaching 17.48% at the time of publication, reporting 2.42 Hong Kong dollars, with a turnover of 50.8039 million Hong Kong dollars. On the news front, China Antibody announced that, after recent communication with the Center for Drug Evaluation (CDE) of the National Medical Products Administration, the company has voluntarily withdrawn the BLA application for Suxibuzilumab for the treatment of rheumatoid arthritis (RA) in China. This decision was made after an internal assessment determined the need for additional early efficacy evidence to support the BLA approval. The company remains confident that Suxibuzilumab will be approved for listing in China and has begun planning a new clinical development plan for the treatment of systemic lupus erythematosus. It is worth noting that the company recently announced that its global first-in-class drug SM03 (Suxibuzilumab) has achieved breakthrough results in preclinical research on systemic lupus erythematosus (SLE). SM03, a monoclonal antibody targeting the CD22 target, with the unique advantage of "regulating the self-immune network through B-cell interaction + protecting organ damage," is expected to address the unmet needs in SLE treatment, providing a better and safer new treatment option for patients worldwide.